Skip to content

Prof Kausik Ray

Professor Kausik Ray

Prof Kausik Ray

BSc (hons), MBChB, FRCP (Lon), FRCP (Ed), MD, MPhil (Cantab), FACC, FESC, FAHA

Prof Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap 2021-2022, Chair for Global Council for Heart Health. National Lead for CVD NHR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now.

About Kausik

He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. His research involves lipids, diabetes and population health serving as global lead for trials and registries. He has over 100,000 citations and since 2018 has been recognised by Clarivate Analytics as among the top 0.1% of authors in global medicine.


Lipds, Lipoproteins, HDL, Glucose, Diabetes, Hypertension, Cardiometabolic Traits, Inflammation, Biomarkers, Epidemiology, Prevention, Trials, ACS, MI, Secondary Prevention, Primary Prevention, Risk Prediction, Genetics

NHS & Academic posts

Honorary Consultant Cardiologist, Imperial College Healthcare NHS Trust
Professor of Public Health, Imperial College London
Director of Imperial Centre for Cardiovascular Disease Prevention
Head of Commercial Trials, Imperial College Trials Unit
Deputy Director, Imperial Clinical Trials Unit, Imperial College London


Reasons why you practice medicine...
Medicine is in my blood. I am a third generation doctor who cares deeply about making a difference to people’s lives and cardiovascular health, which is still the leading cause of death and disability globally.I am also passionate about bringing cutting edge risk assessments and treatments to theentire population, to impact as many people’s health and qualityof life as possible.


3 accomplishments you are most proud of...
1. Leading the global development and implementation of novel cholesteroland diabetes therapies, including Inclisiran and Bempedoic Acid.
2. Since 2018, I have been listed as one of the top 0.1% cited global authors in medicine
3. In 2019, European Union guidelinescited 28 of my papers on how cholesterolshould be detected and managed globally

+44 (0)800 0483 330

Book a Consultation